Investigations on the influence of liver diseases on ampicillin body levels in man.
Ampicillin bioavailability was examined using the urinary excretion method, in healthy subjects and patients with: viral hepatitis, primary hepatocellular carcinoma and hepatosplenic schistosomiasis. A single dose of 500 mg ampicillin was administered intravenously in each case. Viral hepatitis patients gave similar results to healthy subjects. Primary hepatocellular carcinoma and hepatosplenic schistosomiasis patients had reduced drug bioavailability compared to healthy subjects (P less than 0.001).